The Smart Eye Camera (SEC) [
5] used in this study to photograph the anterior segment of the eye was invented and developed by an active ophthalmologist to solve the problems encountered in ophthalmology treatment in Japan and developing countries, an ophthalmic medical device that has been successfully put into practical used as a medical device. SEC is a smartphone attachment that enables observation of various anterior segment structures of the eyes, including the eyelid, conjunctiva, cornea, anterior chamber, iris, lens, and anterior vitreous. This device mirrors the functionalities of conventional slit-lamp microscopy [
6,
7]. Furthermore, SEC facilitates the preliminary estimation and identification of several anterior segment pathologies such as cataracts [
8], primary angle closure [
9], allergic conjunctivitis [
10], and dry eye disease [
11,
12]. Its integration with smartphone technology not only enhances accessibility, but also potentially expands the scope of ophthalmologic diagnostics in various settings. Additionally, an image-filing system using a dedicated application was used to enable remote ophthalmology treatment. The development of SEC has made it possible for anyone to perform eye examinations at any time regardless of location. We are diagnosing videos of the anterior segment of the eye sent via the cloud, and we are conducting research and development to perform the diagnosis using AI to support the diagnosis of ophthalmologists.
Deep learning has been applied in various ways to diagnose conditions that affect the anterior segment of the eye. Applications range from detecting angle-closure in anterior segment optical coherence tomography (AS-OCT) images to diagnosing dry eye disease (DED) and identifying peripheral anterior synechia (PAS). For instance, a deep learning system was developed for angle-closure detection in AS-OCT images, which surpassed previous methods by utilizing a multilevel deep network that captured subtle visual cues from the global anterior segment structure, local iris region, and anterior chamber angle (ACA) patch [
13]. Another study evaluated a deep learning-based method to autonomously detect DED in AS-OCT images, which showed promising results compared to standard clinical dry eye tests [
14]. Deep learning classifiers have also been used to measure peripheral anterior synechia based on swept-source optical coherence tomography (SS-OCT) images, demonstrating good diagnostic performance for gonioscopic angle closure and moderate performance for PAS detection [
15]. In addition, deep learning classifiers have been developed to detect gonioscopic angle closure and primary angle closure disease (PACD) based on a fully automated analysis of AS-OCT images, showing effective detection capabilities [
16]. Another study focused on the diagnostic performance of deep learning for predicting plateau iris in patients with primary angle-closure disease using AS-OCT images, which revealed a high performance in predicting plateau iris [
17]. Finally, a deep learning model was developed for automated detection of eye laterality in anterior segment photographs, which achieved high accuracy and outperformed human experts [
18]. In summary, deep learning has shown significant potential in the diagnosis of various anterior eye conditions, offering automated, accurate, and noninvasive methods that could enhance clinical evaluations and improve access to eye care in high-risk populations [
13,
14,
15,
16,
17,
18]. Deep learning models have shown significant promise in the field of biomedicine, particularly for the diagnosis of systemic diseases. However, there are several challenges associated with their application. One of the primary concerns is the need to guarantee the performance of deep-learning systems once they are deployed in a clinical setting. The inherent flexibility and strength of deep learning also present difficulties in ensuring consistent and reliable outcomes [
19]. Moreover, there is a critical need to establish trust among stakeholders, including clinicians and regulators who require transparent and interpretable decision-making processes. The complexity of deep learning models often leads to a ’black box’ scenario, where the rationale behind their predictions is not easily understood or explained. This lack of transparency can hinder the adoption of deep learning in clinical practice [
19]. In ophthalmology, deep learning has demonstrated potential in automated image analysis for detecting diseases, such as diabetic retinopathy, age-related macular degeneration, and glaucoma. Despite the high accuracy in the initial studies, further testing and research are necessary to validate these technologies clinically. This highlights the challenge of moving from research and development to practical and clinical applications [
20]. A systematic review and meta-analysis comparing the diagnostic accuracy of deep learning algorithms and healthcare professionals found that, while deep learning models can match the performance of healthcare professionals, there is a scarcity of studies that provide externally validated results. Additionally, the review identified the prevalent issue of poor reporting in deep learning studies, which undermines the ability to reliably interpret diagnostic accuracy. The establishment of new reporting standards that address the unique challenges of deep learning is essential for improving the quality of future studies and fostering greater confidence in technology [
21]. In summary, the challenges of applying deep learning models to diagnose systemic diseases include ensuring reliable performance, establishing trust through transparency and interpretability, clinically validating technology, and improving the quality of reporting in deep learning studies [
19,
20,
21]. Deep learning models have shown significant promise in the field of ophthalmology, particularly for the detection and diagnosis of ocular diseases. However, these models have several limitations that must be considered. One of the primary limitations of this study was the need for further testing and clinical validation. Although deep learning models have demonstrated high accuracy in automated image analysis of fundus photographs and optical coherence tomography images, additional research is required to validate these technologies in clinical settings [
22]. Another limitation is the lack of disease specificity and the public generalizability of the models. Despite the decent performance reported in previous studies, most deep learning models developed for identifying systemic diseases based on ocular data lack the specificity required for individual diseases and are not yet generalizable to the broader public for real-world applications [
23]. Furthermore, deep-learning models can be computationally expensive, and deploying them on edge devices may pose a challenge. This is particularly relevant when considering the variety of available models and the potential need for a combination of models to solve a given task. The computational demands of these models may limit their practicality in certain clinical settings [
24]. Lastly, while deep learning models can predict the development of diseases such as glaucoma with reasonable accuracy, they may miss certain cases, especially those with visual field abnormalities, but not glaucomatous optic neuropathy. This indicates that although DL models are powerful tools, they may not yet be able to fully replace the nuanced judgment of trained medical professionals [
25]. In summary, while deep learning models hold great potential for revolutionizing the diagnosis of ocular diseases, their limitations in terms of clinical validation, disease specificity, computational demands, and potential to miss certain cases must be addressed before they can be fully integrated into clinical practice.
The purpose of this study was to develop an AI pipeline to determine the presence of corneal opacity using anterior segment videos captured using a portable sitting microscope and deep learning techniques.